SalubrisBio parent company Salubris Pharmaceuticals announces investment of $10M in Viracta Therapeutics (San Diego, USA) to support development of their kick-and-kill combination cancer therapy
By: jonadmin|Published on: Oct 27, 2020|Categories: |
By: jonadmin|Published on: Oct 27, 2020|Categories: |
Recent Comments